Bioaminex does not sell products directly. Everything begins with lab work and a licensed physician. Please confirm you understand:
Peptide therapies may involve compounds that are prescription-only or investigational. Nothing here should be used without physician supervision and appropriate laboratory monitoring.
The GLP-1 agonist that started the current era of medical weight management — how it works, what the evidence shows, and why it belongs under a provider's care.
Semaglutide is the compound that made "GLP-1" a household term. It's also, like tirzepatide, one of the most counterfeited and gray-market-sold medications in the country — sold online stripped of the dosing schedule, lab monitoring, and screening it was studied with. This page is the straight version.
Semaglutide is a synthetic analog of GLP-1 (glucagon-like peptide-1), a natural gut hormone released after eating. It's approved under three brand names covering diabetes (Ozempic), weight management (Wegovy), and an oral diabetes option (Rybelsus) — and in October 2025 an oral form of semaglutide was also approved for cardiovascular risk reduction in type 2 diabetes, with an oral Wegovy weight-management pill following in December 2025. All forms are prescription-only.
GLP-1 does several things at once: it stimulates insulin release when blood sugar is high, suppresses glucagon (which would otherwise raise blood sugar), slows gastric emptying, and acts on appetite centers in the brain to increase satiety. Semaglutide is engineered to resist the rapid breakdown that limits natural GLP-1 to a few minutes of activity, which is what allows once-weekly dosing.
Semaglutide's approvals rest on large randomized trials — the SUSTAIN program in diabetes and the STEP program in weight management — showing meaningful average reductions in A1C and substantial average weight loss, scaling with dose and treatment duration. As with any GLP-1, trial participants were monitored and supported with lifestyle coaching; the medication was not studied as a standalone intervention. Weight regain after discontinuation is common unless other changes are sustained, which is why providers treat it as a longer-term program rather than a short course.
Gastrointestinal effects — nausea, vomiting, diarrhea, constipation — are the most common, and are usually worst during dose increases, which is why titration schedules exist. Semaglutide carries the same boxed warning as tirzepatide regarding thyroid C-cell tumors seen in rodent studies and is contraindicated in people with a personal or family history of medullary thyroid carcinoma or MEN2 syndrome. It also warrants caution with a history of pancreatitis, diabetic retinopathy, and gallbladder disease — exactly the kind of history a licensed provider screens for before prescribing.
Semaglutide is a legitimate, FDA-approved medication with a substantial trial base behind its approved uses, and real contraindications that require a licensed provider's judgment to screen for. The compound is the same whether it comes from a vetted pharmacy or a gray-market vendor; the safety comes from the supervision around it.
This article is for educational purposes only and is not medical advice. It does not establish a provider-patient relationship. FDA-approval status and clinical information are summarized in general terms and may change; consult a licensed healthcare provider and current prescribing information before making any medical decision. Bioaminex does not sell or dispense semaglutide or any medication.